The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
Open accessAbstract
Purpose Preclinical studies suggest that inhibition of vascular endothelial growth factor (VEGF) improves glioma response to radiotherapy. Bevacizumab, a monoclonal antibody against VEGF, has shown promise in recurrent gliomas, but the safety and efficacy of the concurrent use of bevacizumab with brain irradiation has not been extensively studied. The objectives of this study were to determine the safety and activity of this combination in malignant gliomas. Methods and Materials After prior treatment with standard radiation therapy patients with recurrent glioblastoma (GBM) and anaplastic gliomas (AG) received bevacizumab (10 mg/kg IV) every 2 weeks of 28-day cycles until tumor progression. Patients also received 30 Gy of hypofractionated stereotactic radiotherapy (HFSRT) in 5 fractions after the first cycle of bevacizumab. Results Twenty-five patients (20 GBM and 5 AG) median age of 56 years (range, 30 to 80) and median KPS 90 (range, 70 to 100) received a median of 7 cycles of bevacizumab. One patient did not undergo HFSRT because overlap with prior radiotherapy would exceed the safe dose allowed to the optic chiasm. Three patients discontinued treatment due to: grade 3 CNS intratumoral hemorrhage, wound dehiscence and bowel perforation. Other non-hematologic and hematologic toxicities were transient. No radiation necrosis was seen in these previously-irradiated patients. For the GBM cohort, overall response rate was 50%, 6-month progression free survival was 65%; median overall survival was 12.5 months and 1-year survival was 54%. Discussion Bevacizumab in combination with HFSRT is safe and well tolerated. Radiographic responses, duration of disease control and survival suggest that this regimen is active in recurrent malignant glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., & Kolesnick, R. (2003) · Science · doi:10.1126/science.1082504 · Cited by 1,593
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996
Assumptions in the radiotherapy of glioblastoma
Hochberg, F. H., & Pruitt, A. (1980) · Neurology · doi:10.1212/wnl.30.9.907 · Cited by 992
Therapeutic irradiation and brain injury
Sheline, G. E., Wara, W. M., & Smith, V. (1980) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(80)90175-3 · Cited by 965
Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., et al. (1999) · PubMed · Cited by 947
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
An analysis of dose-effect relationship in the radiotherapy of malignant gliomas
Walker, M. D., Strike, T. A., & Sheline, G. E. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90553-4 · Cited by 854
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
Yamada, Y., Bilsky, M. H., Lovelock, D. M., Venkatraman, E. S., Toner, S., Johnson, J., Zatcky, J., Zelefsky, M. J., & Fuks, Z. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.046 · Cited by 542
Self-citationWedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S. M., Liewehr, D. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4645 · Cited by 518
Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
Koong, A. C., Le, Q. T., Ho, A., Fong, B., Fisher, G., Cho, C., Ford, J., Poen, J., Gibbs, I. C., Mehta, V. K., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.004 · Cited by 444
Ahn, G.-O., & Brown, J. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.11.032 · Cited by 432
Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Kozin, S. V., Boucher, Y., Hicklin, D. J., Böhlen, P., Jain, R. K., & Suit, H. D. (2001) · PubMed · Cited by 291
Zachary, I. (2005) · Neurosignals · doi:10.1159/000088637 · Cited by 266
Radiosurgery for brain metastases: Relationship of dose and pattern of enhancement to local control
Shiau, C.-Y., Sneed, P. K., Shu, H.-K. G., Lamborn, K. R., McDermott, M. W., Chang, S., Nowak, P., Petti, P. L., Smith, V., Verhey, L. J., et al. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00497-x · Cited by 265
Self-citationSathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 261
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
Lamszus, K., Ulbricht, U., Matschke, J., Brockmann, M. A., Fillbrandt, R., & Westphal, M. (2003) · PubMed · Cited by 189
Lai, A., Filka, E., McGibbon, B., Nghiemphu, P. L., Graham, C., Yong, W. H., Mischel, P., Liau, L. M., Bergsneider, M., Pope, W., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.068 · Cited by 183
A comparison of treatment results for recurrent malignant gliomas
Nieder, C., Grosu, A. L., & Molls, M. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0191 · Cited by 158
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Duda, D. G., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.001 · Cited by 155
Goßmann, A., Helbich, T. H., Kuriyama, N., Ostrowitzki, S., Roberts, T. P. L., Shames, D. M., van Bruggen, N., Wendland, M. F., Israel, M. A., & Brasch, R. C. (2002) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10072 · Cited by 151
Cloughesy, T. F., Prados, M. D., Wen, P. Y., Mikkelsen, T., Abrey, L. E., Schiff, D., Yung, W. K. A., Zheng, M., Dimery, I. W., & Friedman, H. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2010b · Cited by 144
Self-citationCzito, B. G., Bendell, J. C., Willett, C. G., Morse, M. A., Blobe, G. C., Tyler, D. S., Thomas, J., Ludwig, K. A., Mantyh, C. R., Ashton, J., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.02.001 · Cited by 134
High-Dose Single-Fraction Radiotherapy: Exploiting a New Biology?
Brown, J. M., & Koong, A. C. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.02.003 · Cited by 114
Narayana, A., Golfinos, J. G., Fischer, I., Raza, S., Kelly, P., Parker, E. C., Knopp, E. A., Medabalmi, P., Zagzag, D., Eagan, P., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.05.062 · Cited by 91
Larsson, H. B. W., & Tofts, P. S. (1992) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910240119 · Cited by 70
Itasaka, S., Komaki, R. K., Herbst, R. S., Shibuya, K., Shintani, T., Hunter, N. R., Onn, A., Bucana, C. D., Milas, L., Ang, K. K., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.10.030 · Cited by 45
Kozin, S. V., Winkler, F., Garkavtsev, I., Hicklin, D. J., Jain, R. K., & Boucher, Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3664 · Cited by 39
Cited by
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Self-citationManagement of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Maier-Hauff, K., Ulrich, F., Nestler, D., Niehoff, H., Wust, P., Thiesen, B., Orawa, H., Budach, V., & Jordan, A. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0389-0 · Cited by 1,429
Standards of care for treatment of recurrent glioblastoma—are we there yet?
Weller, M., Cloughesy, T., Perry, J. R., & Wick, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 771
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C., & Jayson, G. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.2 · Cited by 348
Metadata
- Authors
- Gutin, P. H., Iwamoto, F. M., Beal, K., Mohile, N. A., Karimi, S., Hou, B. L., Lymberis, S., Yamada, Y., Chang, J., & Abrey, L. E.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 75
- Issue
- 1
- Pages
- 156-163
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2137686302
- Cited by
- 370
- References
- 42
- FWCI
- 17.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.